ZVRA

ZEVRA THERAPEUTICS, INC.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001434647 Biotech & Drug Discovery

$9.53 −0.28 (−2.85%)

Oct 26 4:00 PM ET · prev $9.81

Market cap

$613.4M

Small cap

Consensus

Buy

93% Buy or better · 15 analysts

Median target

$24.50

+157% · range $20.00–35.00

Next earnings

Nov 3

in 7 days · EPS est. $0.18

1 year

−14.0%

from $11.08 · Oct 27

30 days

−15.7%

from $11.30

52-week range

$8.10–14.75

−35% from high · low Dec 18

Avg volume 20D

872.8K

shares / day

Short interest

🔒 Subscribers only

Insider net

−$2.5M

0 buyers · 6 sellers · 12 mo

New fund stakes

Q2 2026 13F · 1 exit

Filing reports

analyzed by SecBot

SecBot read MIXED 1 report · 90 days

Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score

Avg score

·High conf. 1/1 ·Next Earnings date, Nov 3, 2026

Strongest NEUTRAL Two ZVRA insiders—the Chief Legal & Compliance Officer and a Director—sold a combined $613K in open-market…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

S Jan 30 to Feb 9 4 days of insider sells: $1.2M by 5 insiders, avg $9.21
R May 6 Zevra Therapeutics reported Q1 2026 net revenue of $36.2M (up 78% Yo…
S May 11 1 insider sell $20.3K at $11.30
S Jun 22 1 insider sell $438.3K at $12.68
S Aug 10 to Aug 14 2 days of insider sells: $613.2K by 2 insiders, avg $11.16
S Oct 12 1 insider sell $224.9K at $11.25

Signal stack

Where each data set points today.

InsidersBEARISH

6 insiders sold $2.5M.
InstitutionsBULLISH

Q2 2026: 20 added (0 new), 10 trimmed or exited.
AnalystsBULLISH

14 of 15 rate it Buy or better. Every target is above the price.
EstimatesFALLING

Current-quarter EPS estimate $0.223 → $0.177 over 90 days. 2 up, 0 down in 30 days.
TrendDOWNTREND

16% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exit

Fund	Move	Shares	Value
FMR LLC	ADD	4,915,717	$70.5M
Woodline Partners LP	ADD	4,785,771	$68.6M
D. E. Shaw & Co., Inc.	ADD	1,306,949	$18.7M
Qube Research & Technologies Ltd	ADD	1,241,343	$17.8M
DIMENSIONAL FUND ADVISORS LP	ADD	958,836	$13.7M
GOLDMAN SACHS GROUP INC	TRIM	545,551	$7.8M
SUSQUEHANNA INTERNATIONAL GROUP, LLP	ADD	309,979	$4.4M
UBS Group AG	TRIM	144,834	$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts

Buy 93% rate it Buy or better

Strong Buy5Buy9Hold1Sell0Strong Sell0

12-month targets · 8 analysts

$9.53 $20.00 $24.50 $35.00

Price is below the lowest target. Median implies +157%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Aug 20, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Aug 7, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy
Aug 6, 2026	Citizens MAINTAIN	MAINTAIN	Market Outperform
Jul 27, 2026	Canaccord Genuity MAINTAIN	MAINTAIN	Buy
Jul 27, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy
Jul 27, 2026	BTIG MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

bought · 0 insiders

$2.5M

sold · 6 insiders

Date	Insider	Type	Value
Oct 12, 2026	McFarlane Neil F. President and CEO	SELL	$224.9K
Oct 10, 2026	McFarlane Neil F. President and CEO	EXERCISE	50,000 sh
Aug 14, 2026	Thompson Rahsaan Chief Legal & Compliance	SELL	$474.8K
Aug 10, 2026	Watton Corey Michael Director	EXERCISE	$61.1K
Aug 10, 2026	Watton Corey Michael Director	SELL	$138.4K
Jun 22, 2026	Thompson Rahsaan Chief Legal & Compliance	SELL	$438.3K
Jun 21, 2026	Thompson Rahsaan Chief Legal & Compliance	EXERCISE	66,667 sh
Jun 4, 2026	Watton Corey Michael Director	AWARD	30,000 sh

Earnings setup

Estimates

Nov 3

reports in 7 days

$0.18

EPS estimate, this quarter

−21%

estimate change, 90 days

2↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

$0.223

90d

$0.193

60d

$0.193

30d

$0.193

$0.177

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	$0.18	$0.13–$0.21	-8.6%	$37.4M
Next Q	$0.19	$0.16–$0.22	-15.9%	$40.2M
Current FY	🔒 Fresh data, subscribers only
Next FY	$1.08	$0.86–$1.30	-18.2%	$177.7M